December 14, 2020

We are pleased to announce $5.3M in funding from Janssen-Cilag Pty Ltd. to support the continuation of the APAC MRDR.  The APAC MRDR received initial funding support from Janssen-Cilag Pty Ltd in 2017 to expand the registry into Asia Pacific countries, including China, Korea, Singapore, Taiwan, and Malaysia. The results from this long-term patient follow-up and analysis of ‘real world’ treatment patterns and their outcomes will inform optimal clinical management strategies for patients with this condition.

Principal investigators Professor Andrew Spencer and Professor Erica Wood, released the following joint statement to mark the milestone: “The range of treatment options available to patients with myeloma has increased dramatically over the last 30 years, resulting in improved survival. The APAC MRDR, in addition to enabling clinicians to benchmark against national and international standards, will also serve as a platform for a wide range of studies such as health economics analyses, and a basis from which to explore the viability of more targeted, and costly, interventional studies. Thanks to Janssen-Cilag Pty Ltd, the APAC MRDR project team will be able to continue and expand this valuable work.”

We would like to extend our sincere thanks all the researchers and staff involved in the APAC MRDR for their fantastic contributions. We look forward to the continuing these collaborations.